JP7284518B2 - テロメア結合タンパク質を阻害する化合物、及びそれを含むテロメア結合タンパク質阻害剤 - Google Patents
テロメア結合タンパク質を阻害する化合物、及びそれを含むテロメア結合タンパク質阻害剤 Download PDFInfo
- Publication number
- JP7284518B2 JP7284518B2 JP2020508284A JP2020508284A JP7284518B2 JP 7284518 B2 JP7284518 B2 JP 7284518B2 JP 2020508284 A JP2020508284 A JP 2020508284A JP 2020508284 A JP2020508284 A JP 2020508284A JP 7284518 B2 JP7284518 B2 JP 7284518B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydrogen
- telomere
- compound
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims description 104
- 102000010823 Telomere-Binding Proteins Human genes 0.000 title claims description 44
- 108010038599 Telomere-Binding Proteins Proteins 0.000 title claims description 44
- 229940121649 protein inhibitor Drugs 0.000 title claims description 12
- 239000012268 protein inhibitor Substances 0.000 title claims description 12
- 239000000126 substance Substances 0.000 claims description 39
- 108091035539 telomere Proteins 0.000 claims description 39
- 108010033710 Telomeric Repeat Binding Protein 2 Proteins 0.000 claims description 36
- 102000007316 Telomeric Repeat Binding Protein 2 Human genes 0.000 claims description 36
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 239000001257 hydrogen Substances 0.000 claims description 34
- 102000055501 telomere Human genes 0.000 claims description 33
- 210000003411 telomere Anatomy 0.000 claims description 33
- 150000002431 hydrogen Chemical class 0.000 claims description 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 239000011593 sulfur Substances 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 101000741885 Homo sapiens Protection of telomeres protein 1 Proteins 0.000 claims description 4
- 102100038745 Protection of telomeres protein 1 Human genes 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical group [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 2
- 102000007315 Telomeric Repeat Binding Protein 1 Human genes 0.000 claims 1
- 108010033711 Telomeric Repeat Binding Protein 1 Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 description 80
- 108020004707 nucleic acids Proteins 0.000 description 80
- 150000007523 nucleic acids Chemical class 0.000 description 80
- 210000004027 cell Anatomy 0.000 description 42
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 238000004904 shortening Methods 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 210000004940 nucleus Anatomy 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000030833 cell death Effects 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 230000009758 senescence Effects 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000002804 Ataxia Telangiectasia Mutated Proteins Human genes 0.000 description 4
- 102000003952 Caspase 3 Human genes 0.000 description 4
- 108090000397 Caspase 3 Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 230000008045 co-localization Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 102000044158 nucleic acid binding protein Human genes 0.000 description 4
- 108700020942 nucleic acid binding protein Proteins 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 230000000171 quenching effect Effects 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101001128138 Homo sapiens NACHT, LRR and PYD domains-containing protein 2 Proteins 0.000 description 3
- 101000981336 Homo sapiens Nibrin Proteins 0.000 description 3
- 102100024403 Nibrin Human genes 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000003505 heat denaturation Methods 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical class NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000037051 Chromosomal Instability Diseases 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000929940 Homo sapiens Adrenocortical dysplasia protein homolog Proteins 0.000 description 1
- 101000730577 Homo sapiens p21-activated protein kinase-interacting protein 1 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010293 colony formation assay Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 102100032579 p21-activated protein kinase-interacting protein 1 Human genes 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
- C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
- C07C217/92—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the nitrogen atom of at least one of the amino groups being further bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/33—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring
- C07C323/35—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring the thio group being a sulfide group
- C07C323/37—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring the thio group being a sulfide group the sulfur atom of the sulfide group being further bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
上記化学式中において、
R1は、酸素又は硫黄であり、
R2~R6は、互いに独立して、水素、炭素原子数が1~6のアルキル基、炭素原子数が1~6のアルコキシ基、炭素原子数が1~6のアシル基及びニトロ基から選択される。
R1は、酸素又は硫黄であり、
R2及びR4は、互いに独立して、水素又はニトロ基であり、
R3は、水素、ニトロ基、メチル基、メトキシ基又はブチル基であり、
R5は、水素、メチル基、メトキシ基又はアセチル基であり、
R6は、水素又はブチル基であることが好ましい。
なお、上記化学式中において、
R1は、酸素又は硫黄であり、
R2~R6は、互いに独立して、水素、炭素原子数が1~6のアルキル基、炭素原子数が1~6のアルコキシ基、炭素原子数が1~6のアシル基及びニトロ基から選択される。
R1は、酸素又は硫黄であり、
R2及びR4は、互いに独立して、水素又はニトロ基であり、
R3は、水素、ニトロ基、メチル基、メトキシ基又はブチル基であり、
R5は、水素、メチル基、メトキシ基又はアセチル基であり、
R6は、水素又はブチル基であることが好ましい。
・核酸A1:第一のヌクレオチド配列および第二のヌクレオチド配列(末端配列)を有する核酸一本鎖。
・核酸A2:第一のヌクレオチド配列に対応する配列および第三のヌクレオチド配列(末端配列)を有する核酸一本鎖。
・核酸B1:第二のヌクレオチド配列に対応する配列(末端配列)および第四のヌクレオチド配列を有する核酸一本鎖。
・核酸B2:第三のヌクレオチド配列に対応する配列(末端配列)および第四のヌクレオチド配列に対応する配列を有する核酸一本鎖。
95℃ 120秒 - 90℃ 30秒 - 85℃ 90秒 - 80℃ 90秒 - 77℃ 90秒 - 75℃ 90秒 - 72℃ 90秒 - 70℃ 90秒 - 67℃ 90秒 - 65℃ 90秒 - 62℃ 90秒 - 60℃ 90秒 - 57℃ 90秒 - 55℃ 90秒 - 52℃ 90秒 - 50℃ 90秒 - 47℃ 90秒 - 45℃ 90秒 - 42℃ 90秒 - 40℃ 90秒 - 37℃ 90秒 - 35℃ 90秒 - 32℃ 90秒 - 30℃ 90秒。
TLM-01-5F:
5’ FAM- AGTTGAGTTAGGGTTAGGGT TAGGGTTAGG GCAGGcggtg tctcgctcgc 3’(配列番号1)
TLM-02-3D:
5’ gcgagcgagacaccgCCTGC CCTAACCCTA ACCCTAACCC TAACTCAACT -Dabcyl 3’(配列番号2)
TLM-05:
5’AGTTGAGTTA GGGTTAGGGT TAGGGTTAGG GCAGGcacca caccattccc 3’(配列番号3)
TLM-06:
5’gggaatggtg tggtgCCTGC CCTAACCCTA ACCCTAACCC TAACTCAACT 3’(配列番号4)
なお、上記化学式中において、
R1は、酸素又は硫黄であり、
R2及びR4は、互いに独立して、水素又はニトロ基であり、
R3は、水素、ニトロ基、メチル基、メトキシ基又はブチル基であり、
R5は、水素、メチル基、メトキシ基又はアセチル基であり、
R6は、水素又はブチル基である。
Claims (13)
- 上記化学式中において、
R1は、酸素であり、
R2及びR4は、互いに独立して、水素又はニトロ基であり、
R3は、水素、ニトロ基、メチル基、メトキシ基又はブチル基であり、
R5は、水素、メチル基、メトキシ基又はアセチル基であり、
R6は、水素又はブチル基である、
ことを特徴とする請求項1に記載の化合物。 - 上記化学式中において、
R1は、酸素又は硫黄であり、
R2及びR4は、互いに独立して、水素又はニトロ基であり、
R3は、水素、ニトロ基、メチル基、メトキシ基又はブチル基であり、
R5は、水素、メチル基、メトキシ基又はアセチル基であり、
R6は、水素又はブチル基である、請求項4に記載のテロメア結合タンパク質阻害剤。 - 前記テロメア結合タンパク質は、TRF1、TRF2又はPOT1であることを特徴とする請求項4に記載のテロメア結合タンパク質阻害剤。
- 上記化学式中において、
R1は、酸素又は硫黄であり、
R2及びR4は、互いに独立して、水素又はニトロ基であり、
R3は、水素、ニトロ基、メチル基、メトキシ基又はブチル基であり、
R5は、水素、メチル基、メトキシ基又はアセチル基であり、
R6は、水素又はブチル基である、請求項8に記載の医薬組成物。 - 上記化学式中において、
R1は、酸素又は硫黄であり、
R2及びR4は、互いに独立して、水素又はニトロ基であり、
R3は、水素、ニトロ基、メチル基、メトキシ基又はブチル基であり、
R5は、水素、メチル基、メトキシ基又はアセチル基であり、
R6は、水素又はブチル基である、
ことを特徴とする請求項11に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018052087 | 2018-03-20 | ||
JP2018052087 | 2018-03-20 | ||
PCT/JP2019/010480 WO2019181714A1 (ja) | 2018-03-20 | 2019-03-14 | テロメア結合タンパク質を阻害する化合物、及びそれを含むテロメア結合タンパク質阻害剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2019181714A1 JPWO2019181714A1 (ja) | 2021-04-08 |
JP7284518B2 true JP7284518B2 (ja) | 2023-05-31 |
Family
ID=67987628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020508284A Active JP7284518B2 (ja) | 2018-03-20 | 2019-03-14 | テロメア結合タンパク質を阻害する化合物、及びそれを含むテロメア結合タンパク質阻害剤 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20210024455A1 (ja) |
JP (1) | JP7284518B2 (ja) |
WO (1) | WO2019181714A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023182897A1 (en) * | 2022-03-25 | 2023-09-28 | Politechnika Gdańska | Inhibitors of interactions between trf1-tin2 or trf2-tin2 telomeric proteins for use in anticancer therapy |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001072592A (ja) | 1999-07-01 | 2001-03-21 | Kyowa Hakko Kogyo Co Ltd | テロメラーゼ阻害剤 |
WO2001030771A1 (fr) | 1999-10-28 | 2001-05-03 | Kyowa Hakko Kogyo Co., Ltd. | Derives de thiazolidinedione |
WO2002044120A1 (en) | 2000-11-29 | 2002-06-06 | Karo Bio Ab | Compounds active at the glucocorticoid receptor iii |
JP2004524349A (ja) | 2001-03-23 | 2004-08-12 | アベンティス・ファーマ・ソシエテ・アノニム | 化学的誘導体および抗テロメラーゼ剤としてのその使用 |
WO2009093667A1 (ja) | 2008-01-22 | 2009-07-30 | Hiroshima University | 核酸結合蛋白質アッセイ法およびキット |
JP2012507504A (ja) | 2008-10-31 | 2012-03-29 | アンスティテュ・キュリ | 癌の処置用のポリ−ヘテロアリール誘導体 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07238066A (ja) * | 1994-02-28 | 1995-09-12 | Green Cross Corp:The | ベンゼンスルホン酸誘導体、その製造法およびその用途 |
WO2017115753A1 (ja) * | 2015-12-28 | 2017-07-06 | コニカミノルタ株式会社 | 架橋化合物、有機エレクトロルミネッセンス素子材料、有機エレクトロルミネッセンス素子、表示装置及び照明装置 |
-
2019
- 2019-03-14 WO PCT/JP2019/010480 patent/WO2019181714A1/ja active Application Filing
- 2019-03-14 US US16/982,517 patent/US20210024455A1/en not_active Abandoned
- 2019-03-14 JP JP2020508284A patent/JP7284518B2/ja active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001072592A (ja) | 1999-07-01 | 2001-03-21 | Kyowa Hakko Kogyo Co Ltd | テロメラーゼ阻害剤 |
WO2001030771A1 (fr) | 1999-10-28 | 2001-05-03 | Kyowa Hakko Kogyo Co., Ltd. | Derives de thiazolidinedione |
WO2002044120A1 (en) | 2000-11-29 | 2002-06-06 | Karo Bio Ab | Compounds active at the glucocorticoid receptor iii |
JP2004524349A (ja) | 2001-03-23 | 2004-08-12 | アベンティス・ファーマ・ソシエテ・アノニム | 化学的誘導体および抗テロメラーゼ剤としてのその使用 |
WO2009093667A1 (ja) | 2008-01-22 | 2009-07-30 | Hiroshima University | 核酸結合蛋白質アッセイ法およびキット |
JP2012507504A (ja) | 2008-10-31 | 2012-03-29 | アンスティテュ・キュリ | 癌の処置用のポリ−ヘテロアリール誘導体 |
Non-Patent Citations (6)
Title |
---|
Database REGISTRY,2001年,RN 352638-37-0,Retrieved from STN international [online] ;retrieved on 24 April 2019 |
城間 喜智 他,DSE-FREAT assayを応用して得られたTRF2-telomere DNA結合阻害剤,第21回日本がん分子標的治療学会学術集会プログラム・抄録集,2017年,W7-5 |
城間 喜智 他,DSE-FRET assayを用いたテロメア結合タンパク質阻害剤開発と機能解析,日本生化学会大会,2017年,2P-1435 |
城間 喜智 他,DSE-FRET法を用いて得られたテロメア結合タンパク質TRF2阻害剤,第20回日本がん分子標的治療学会学術集会プログラム・抄録集,2016年,P24-2 |
城間 喜智 他,テロメア結合タンパク質TRF2の結合阻害剤ががん細胞に及ぼす影響,第76日本癌学会学術総会抄録集,2017年,J-3119 |
城間 喜智,DSE-FRET法を用いたテロメア結合タンパク質 TRF2阻害剤の探索,第19回日本がん分子標的治療学会学術集会プログラム・抄録集,2015年,P3-3 |
Also Published As
Publication number | Publication date |
---|---|
WO2019181714A1 (ja) | 2019-09-26 |
JPWO2019181714A1 (ja) | 2021-04-08 |
US20210024455A1 (en) | 2021-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | Circular RNA DOCK1 promotes bladder carcinoma progression via modulating circDOCK1/hsa‐miR‐132‐3p/Sox5 signalling pathway | |
Alekseyenko et al. | Ectopic protein interactions within BRD4–chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma | |
Zhang et al. | Breast cancer metastasis suppressor OTUD1 deubiquitinates SMAD7 | |
Zhou et al. | Regulation of Hippo/YAP signaling and Esophageal Squamous Carcinoma progression by an E3 ubiquitin ligase PARK2 | |
Bunch et al. | Transcriptional elongation requires DNA break-induced signalling | |
Malik et al. | Targeting the MLL complex in castration-resistant prostate cancer | |
Xie et al. | miR-106a promotes growth and metastasis of non-small cell lung cancer by targeting PTEN | |
Ahmed et al. | Telomerase does not counteract telomere shortening but protects mitochondrial function under oxidative stress | |
Singh et al. | MiCEE is a ncRNA-protein complex that mediates epigenetic silencing and nucleolar organization | |
Isozaki et al. | Therapy-induced APOBEC3A drives evolution of persistent cancer cells | |
Yong et al. | Ribosomal proteins RPS11 and RPS20, two stress-response markers of glioblastoma stem cells, are novel predictors of poor prognosis in glioblastoma patients | |
Sen et al. | Fibronectin induces matrix metalloproteinase-9 (MMP-9) in human laryngeal carcinoma cells by involving multiple signaling pathways | |
US20170137418A1 (en) | Small molecular probes, processes and use thereof | |
JP2008522615A (ja) | ドセタキセル耐性または感受性の測定方法 | |
Gomez-Acevedo et al. | Identification of putative biomarkers for Infantile Hemangiomas and Propranolol treatment via data integration | |
JP2016506362A (ja) | 合成致死性および癌の治療 | |
Bambouskova et al. | New regulatory roles of galectin-3 in high-affinity IgE receptor signaling | |
Wang et al. | RETRACTED ARTICLE: microRNA-769 is downregulated in colorectal cancer and inhibits cancer progression by directly targeting cyclin-dependent kinase 1 | |
JP7284518B2 (ja) | テロメア結合タンパク質を阻害する化合物、及びそれを含むテロメア結合タンパク質阻害剤 | |
Laliotis et al. | RETRACTED ARTICLE: AKT3-mediated IWS1 phosphorylation promotes the proliferation of EGFR-mutant lung adenocarcinomas through cell cycle-regulated U2AF2 RNA splicing | |
Kim et al. | The SET domain Is essential for Metnase functions in replication restart and the 5’end of SS-overhang cleavage | |
US20190147975A1 (en) | Sf3b1 suppression as a therapy for tumors harboring sf3b1 copy loss | |
EP2726869B1 (en) | Somatic mutations in atrx in brain cancer | |
CA3211847A1 (en) | Circular rnas for diagnosis of depression and prediction of response to antidepressant treatment | |
Jiang et al. | Post-GWAS functional analysis identifies CUX1 as a regulator of p16INK4a and cellular senescence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A5211 Effective date: 20200907 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220304 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230307 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230324 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230509 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230512 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7284518 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |